31 patents currently held
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
7 more records may belong here and await a decision; they are not counted.
The next term ends in Feb 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
11
Ending by 2030
Feb 2027
Next term end
20
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Dec 2027 · High confidence
Also notable
Ends Feb 2028 · High confidence
Also notable
Ends Oct 2032 · High confidence
Novel Anxiolytic Compounds
US 8,293,737
The largest patent family in this portfolio, 9 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Substituted Benzofurans, Benzothiophenes, Benzoselenophenes and Indoles and Their Use as Tubulin Polymerisation Inhibitors
US 8,198,466
The largest patent family in this portfolio, 6 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2028.
Methods of Inhibiting Solid Tumor Growth by Administering GPR49 Antibodies
US 9,221,906
Granted 2015 and renewed at every maintenance window due so far. Protection runs to 2032. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Notable
Ends Apr 2035 · High confidence
Cited by 15 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
now held by Carina Biotech Limited
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 23, 2026The maintenance fee for Antibody and Checkpoint Inhibitor Combination Therapy (US 11,655,304) comes due Nov 23, 2026. Unpaid by May 24, 2027, it lapses early.
- 1 fee due Mar 15, 2027The maintenance fee for Methods for Preparing Naphthyridines (US 9,133,188) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
- 3 fees due Jun 29, 2027
- 1 fee due Jul 30, 2027The maintenance fee for Modulators of Ion Channel Receptors and Uses Thereof (US 11,884,673) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.
- 1 fee due Sep 24, 2027The maintenance fee for Methods of Blocking Cancer Stem Cell Growth (US 10,598,653) comes due Sep 24, 2027. Unpaid by Mar 24, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 20 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Novel Anxiolytic Compounds | 8 in force | to Dec 2027 |
| Substituted Benzofurans, Benzothiophenes, Benzoselenophenes and Indoles and Their Use as Tubulin Polymerisation Inhibitors | 3 in force | to Feb 2028 |
| Modulators of Ion Channel Receptors and Uses Thereof | 2 in force | to May 2039 |
| Methods of Inhibiting Solid Tumor Growth by Administering GPR49 Antibodies | 2 in force | to Oct 2032 |
| Cyclic compounds as receptor modulating therapeutics and methods and uses thereof | 1 in force | to Dec 2041 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,346,842 | Substituted Benzofurans, Benzothiophenes, Benzoselenophenes and Indoles and Their Use as Tubulin Polymerisation Inhibitors In force · High confidence | In force | High confidence | |
| US 10,213,409 | Substituted Benzofurans, Benzothiophenes, Benzoselenophenes and Indoles and Their Use as Tubulin Polymerisation Inhibitors In force · Low confidence | In force | Low confidence | |
| US 8,551,990 | Novel Anxiolytic Compounds In force · Medium confidence | In force | Medium confidence | |
| US 8,614,212 | Novel Anxiolytic Compounds In force · Medium confidence | In force | Medium confidence | |
| US 8,906,912 | Novel Anxiolytic Compounds In force · Medium confidence | In force | Medium confidence | |
| US 9,573,945 | Novel Anxiolytic Compounds In force · High confidence | In force | High confidence | |
| US 9,975,892 | Novel Anxiolytic Compounds In force · Medium confidence | In force | Medium confidence | |
| US 10,233,181 | Novel Anxiolytic Compounds In force · Medium confidence | In force | Medium confidence | |
| US 10,954,231 | Novel Anxiolytic Compounds In force · High confidence | In force | High confidence | |
| US 8,293,737 | Novel Anxiolytic Compounds In force · High confidence | In force | High confidence |
Also on record, not counted in the 31: 4 patents in force now held by others · 26 patents ended · 4 applications pending · 31 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.